Clinical Trial Update: Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib and fluzoparib with or without adebrelimab in previously treated TP53-mutant advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Apatinib (apatinib)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: NSCLC, Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN